Hosted on MSN11d
Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earningsOn Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat ...
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...
Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a ...
The Food and Drug Administration (FDA) approved Johnson & Johnson's ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression. Spravato, approved as a ...
"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...
Last month, the U.S. Food and Drug Administration issued a complete response letter (CRL) to Johnson & Johnson's Biologics ...
J&J on Tuesday said the green light makes Spravato the first and only monotherapy for adults with major depressive disorder who have had an inadequate response to at least two oral antidepressants.
HealthDay on MSN11d
FDA Approves Spravato Nasal Spray for Treatment-Resistant DepressionWEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine ...
The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback